Metagenomi Therapeutics, Inc. - 8-K Filing

Metagenomi Therapeutics disclosed $120.7 million in cash as of Q2 2026, with runway through Q4 2027. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · September 22, 2026, 10:03 UTC

Tickers: $MGX

Read the full article at SEC EDGAR

More Regulatory news

LiveRamp Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:52 UTC
Presurance Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 16:43 UTC
EXPEDITORS INTERNATIONAL OF WASHINGTON INC - 8-K Filing SEC EDGAR · November 12, 2026, 16:42 UTC
AUDIOEYE INC - 10-Q Filing SEC EDGAR · October 26, 2026, 21:11 UTC
ROCKWELL AUTOMATION, INC - 10-K Filing SEC EDGAR · November 12, 2026, 16:35 UTC
United KSK Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 16:29 UTC
AMERICAN SHARED HOSPITAL SERVICES - 8-K Filing SEC EDGAR · November 12, 2026, 16:27 UTC
VIVIC CORP. - 10-K Filing SEC EDGAR · November 12, 2026, 16:26 UTC
WOLVERINE WORLD WIDE INC /DE/ - 10-Q Filing SEC EDGAR · November 12, 2026, 16:24 UTC
BlueOne Technologies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:20 UTC